-
Product Insights
Acurity Health/ Evolution Healthcare/ Vital HPT – Newtown Wakefield Hospital Redevelopment – Wellington
Equip yourself with the essential tools needed to make informed and profitable decisions with our Acurity Health/ Evolution Healthcare/ Vital HPT - Newtown Wakefield Hospital Redevelopment - Wellington report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...
-
Product Insights
Burghley HPT/ Gummer Leathes – Stamford Residential Community – Lincolnshire
Equip yourself with the essential tools needed to make informed and profitable decisions with our Burghley HPT/ Gummer Leathes - Stamford Residential Community - Lincolnshire report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – HPT-721
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry HPT-721 Drug Details HPT-721 is under development for the prevention of painful itching and...
-
Product Insights
Net Present Value Model: Regpara
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Regpara Drug Details Cinacalcet hydrochloride (Sensipar/...
-
Product Insights
Net Present Value Model: Sensipar/Mimpara
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Sensipar/Mimpara Drug Details Cinacalcet hydrochloride (Sensipar/...
-
Sector Analysis
Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) – Epidemiology Forecast to 2030
Diagnosed prevalent cases of chronic kidney disease (CKD) in the seven major markets (7MM*) combined is expected to increase from 8.57 million cases in 2020 to 9.44 million in 2030, at an annual growth rate (AGR) of 1.02%, according to GlobalData, a leading data and analytics company. Of the 7MM, the diagnosed prevalent cases of CKD in the US are expected to increase at an AGR of 1.59% between 2020Â and 2030, followed by Spain (1.51%), and France (1.19%). The major...
-
Sector Analysis
Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) – Global Drug Forecast and Market Analysis to 2030
CKD is a chronic condition in which patients suffer from an irreversible and progressive loss in renal function over many months or years, ultimately resulting in end-stage renal disease and the requirement for renal replacement therapy. CKD manifests when both kidneys are damaged sufficiently to hinder the removal of metabolic products from the body and the ability to provide mineral balance. The Centers for Disease Control and Prevention states that approximately 96% of people with kidney damage or mild to...
-
Sector Analysis
OpportunityAnalyzer: Late – Stage Chronic Kidney Disease – Opportunity Analysis and Forecasts to 2026
The late-stage chronic kidney disease (CKD) - Induced Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia market is expected to undergo significant growth over the next ten years across the seven major markets (7MM) covered in this report (US, France, Germany, Italy, Spain, UK, and Japan). The main driver of this expansion will be the dramatic increase in disease prevalence. According to primary research, GlobalData has determined that there is a high level of unmet need remaining for CKD patients. Despite the launch of...